{"filings":[{"id":746398,"accession_number":"0001193125-26-248210","cik":1850270,"company_name":"PROKIDNEY CORP.","ticker":"PROK","form_type":"8-K","filed_at":"2026-05-29T20:02:40+00:00","items":["5.07"],"status":"ready","headline":"ProKidney Corp. announces 2026 annual meeting results; three directors elected","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders elected William F. Doyle, Alan M. Lotvin, and Brian J.G. Pereira to three-year board terms.","Doyle received 196,164,585 For votes; Lotvin 193,179,768; Pereira 197,002,580; each had ~42.6M broker non-votes.","Ratification of Ernst & Young as auditor for FY 2026 passed with 239,091,167 For, 729,165 Against, 382,882 Abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":671918118.718232,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":460036,"accession_number":"0001193125-26-225848","cik":1850270,"company_name":"PROKIDNEY CORP.","ticker":"PROK","form_type":"8-K","filed_at":"2026-05-15T15:49:09+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"ProKidney Q1 net loss $42.6M; Phase 3 PROACT 1 enrollment on track for mid-2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $42.6M for Q1 2026; cash & equivalents $224.9M supporting operations into mid-2027.","Phase 3 PROACT 1 enrollment on track to complete mid-2026; pivotal topline results expected Q2 2027.","FDA confirmed eGFR slope as surrogate endpoint for accelerated approval under RMAT designation.","Phase 2 REGEN-007 showed 4.6 mL/min/1.73m² improvement in annual eGFR slope decline.","R&D expenses $33.8M (+24% YoY) driven by PROACT 1; G&A expenses $11.3M (-21% YoY)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":226000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":671918118.718232,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109920,"accession_number":"0001193125-26-113893","cik":1850270,"company_name":"PROKIDNEY CORP.","ticker":"PROK","form_type":"8-K","filed_at":"2026-03-18T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ProKidney reports 2025 net loss $151.6M, cash $270M; Phase 3 PROACT 1 on track for mid-2026 enrollment","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $151.6M in 2025 vs $163.3M in 2024; no revenue as pre-revenue cell therapy company.","Cash and marketable securities $270.0M at Dec 31, 2025, down from $358.3M; runway into mid-2027.","Phase 3 PROACT 1 enrollment for accelerated approval (n~360) on track for mid-2026; top-line eGFR slope data Q2 2027.","FDA confirmed in July 2025 Type B meeting that eGFR slope can serve as surrogate endpoint for accelerated approval.","Positive Phase 2 REGEN-007 results presented at ASN Kidney Week 2025 and published in CJASN."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":671918118.718232,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109919,"accession_number":"0001193125-26-033594","cik":1850270,"company_name":"PROKIDNEY CORP.","ticker":"PROK","form_type":"8-K","filed_at":"2026-02-02T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"ProKidney updates PROACT 1 enrollment target to ~470; confirmatory readout now H2 2029","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Enrollment target increased to ~470 subjects in Phase 3 PROACT 1 (REGEN-006) study.","Surrogate endpoint (eGFR slope) topline data readout still anticipated Q2 2027.","Confirmatory endpoint (composite time-to-event) topline data readout now anticipated H2 2029.","Statistical powering assumptions unchanged for both surrogate and confirmatory analyses."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":671918118.718232,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109918,"accession_number":"0001193125-26-009807","cik":1850270,"company_name":"PROKIDNEY CORP.","ticker":"PROK","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"ProKidney updates investor presentation; no financial details disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company posted updated investor presentation on January 12, 2026.","Presentation available on ProKidney's investor relations website.","No specific changes, milestones, or financial data were provided in the filing.","Presentation intended for use with investors and analysts."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":671918118.718232,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126502,"accession_number":"0001193125-25-274314","cik":1850270,"company_name":"PROKIDNEY CORP.","ticker":"PROK","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ProKidney reports Q3 net loss $35.8M, cash $271.7M; Phase 3 PROACT 1 enrollment >50%, topline Q2 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net loss before noncontrolling interest $35.8M vs $41.1M YoY; R&D expenses $26.8M.","Cash and equivalents $271.7M, expected to fund operations into mid-2027.","Phase 3 PROACT 1 accelerated approval analysis: >50% of ~360 patients enrolled, topline results Q2 2027.","FDA confirmed eGFR slope as surrogate endpoint for BLA under accelerated approval; RMAT designation continues.","Phase 2 REGEN-007 data at ASN: 78% improvement in eGFR decline (p<0.001); well tolerated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":668000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":671918118.718232,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126501,"accession_number":"0001193125-25-242565","cik":1850270,"company_name":"PROKIDNEY CORP.","ticker":"PROK","form_type":"8-K","filed_at":"2025-10-17T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"ProKidney enters agreement to sell Greensboro property for $19.1M cash","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sale of real property in Greensboro, NC to Northpoint Development, LLC for approx. $19.1M cash.","Prior purchase agreement with Williams Development Group was terminated; new deal signed Oct 17, 2025.","Agreement contains customary representations and closing conditions; full text to be filed in 10-K.","Transaction structured through wholly owned subsidiary ProKidney Acquisition Company, LLC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":671918118.718232,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143248,"accession_number":"0000950170-25-107357","cik":1850270,"company_name":"PROKIDNEY CORP.","ticker":"PROK","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ProKidney Q2 net loss $37M; FDA agrees eGFR slope for accelerated approval; Phase 2 shows 78% eGFR improvement","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FDA confirmed eGFR slope as surrogate endpoint for accelerated approval of rilparencel; topline data from PROACT 1 expected Q2 2027.","Phase 2 REGEN-007: eGFR slope improved 78% (from -5.8 to -1.3 mL/min/1.73m²/yr) in Group 1 (n=24), p<0.001; no SAEs related.","Cash and equivalents $294.7M as of June 30, 2025, down from $328.5M; funds operations into mid-2027.","Q2 net loss $37.0M vs $38.5M in prior year; R&D expenses $25.9M down from $29.4M.","More than half of ~350 patients for accelerated approval analysis enrolled in Phase 3 PROACT 1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":451000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":671918118.718232,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143242,"accession_number":"0001140361-25-026049","cik":1850270,"company_name":"PROKIDNEY CORP.","ticker":"PROK","form_type":"8-K12B/A","filed_at":"2025-07-16T23:59:59+00:00","items":["1.01","3.03","5.02","5.03","8.01","9.01"],"status":"ready","headline":"ProKidney completes domestication from Cayman Islands to Delaware, effective July 1, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Each Cayman Class A and B ordinary share converted one-for-one into Delaware Class A and B common stock.","New Delaware certificate of incorporation and bylaws adopted; CUSIP changed to 74291D 104.","Amended and restated Tax Receivable, Lock-Up, and Exchange Agreements entered into.","ProKidney Holdings LLC governance established via Second A&R LLC Agreement.","Incentive equity and stock purchase plans amended to reflect domestication."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":671918118.718232,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143247,"accession_number":"0001193125-25-159041","cik":1850270,"company_name":"PROKIDNEY CORP.","ticker":"PROK","form_type":"8-K","filed_at":"2025-07-15T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"ProKidney gains FDA alignment on accelerated approval pathway for rilparencel; topline data Q2 2027","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA confirmed eGFR slope as surrogate endpoint for accelerated approval of rilparencel in CKD with type 2 diabetes.","Effect size of at least 1.5 mL/min/1.73m2/year required versus sham; nearly half of required patients enrolled.","Phase 3 PROACT 1 can serve as both the accelerated and confirmatory study; confirmatory readout timing in 1H 2026.","Topline data for accelerated approval BLA submission anticipated in Q2 2027.","Rilparencel holds RMAT designation; CEO called it a critical regulatory milestone."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":671918118.718232,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143246,"accession_number":"0001193125-25-158806","cik":1850270,"company_name":"PROKIDNEY CORP.","ticker":"PROK","form_type":"8-K","filed_at":"2025-07-14T23:59:59+00:00","items":["1.01","1.02","8.01","9.01"],"status":"ready","headline":"ProKidney enters new $200M ATM equity facility with Jefferies, terminates prior agreement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New Open Market Sale Agreement with Jefferies LLC allows sale of up to $200M of Class A common stock.","Jefferies will receive up to 3.0% compensation of gross proceeds from any sales under the agreement.","Prior $200M ATM agreement dated Jan 19, 2024 was mutually terminated effective July 14, 2025.","Company has no obligation to sell shares; sales may occur through various methods including Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":671918118.718232,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143245,"accession_number":"0000950170-25-094445","cik":1850270,"company_name":"PROKIDNEY CORP.","ticker":"PROK","form_type":"8-K","filed_at":"2025-07-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"ProKidney reports statistically significant Phase 2 REGEN-007 results for rilparencel; FDA Type B meeting set","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["eGFR slope improved 78% from -5.8 to -1.3 mL/min/1.73m² per year (p<0.001) in Group 1 (n=24).","Group 2 showed 50% improvement but not statistically significant (p=0.085); evidence of dose response.","No rilparencel-related serious adverse events observed; safety consistent with prior studies and kidney biopsy.","FDA Type B meeting set for summer 2025 to confirm eGFR slope as surrogate endpoint for accelerated approval.","Full results submitted to ASN 2025 Kidney Week as late-breaking clinical trial."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":671918118.718232,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143243,"accession_number":"0001140361-25-024839","cik":1850270,"company_name":"PROKIDNEY CORP.","ticker":"PROK","form_type":"8-K12B","filed_at":"2025-07-03T23:59:59+00:00","items":["1.01","3.03","5.02","5.03","8.01","9.01"],"status":"ready","headline":"ProKidney completes Cayman-to-Delaware domestication effective July 1, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Each Cayman Class A and Class B ordinary share converted 1:1 into Delaware Class A or Class B common stock.","ProKidney Delaware issued amended tax receivable, lock-up, and exchange agreements on same terms as prior Cayman agreements.","Adopted new Certificate of Incorporation and Bylaws under DGCL; CUSIP changed to 74291D 104 as of July 2, 2025.","Class A common stock continues trading on Nasdaq under symbol PROK; no change in ticker or capital structure.","Restructuring includes subsidiary reorganization via ProKidney Holdings, LLC and ProKidney IPCo, LLC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":671918118.718232,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143244,"accession_number":"0001140361-25-024348","cik":1850270,"company_name":"PROKIDNEY CORP.","ticker":"PROK","form_type":"8-K","filed_at":"2025-07-01T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"ProKidney Corp. completes redomestication to Delaware, effective July 1, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved the change at the May 29, 2025 Annual General Meeting.","Each Class A and Class B ordinary share converted to one share of common stock (same class).","Trading symbol remains 'PROK' on Nasdaq; CUSIP changed to 74291D 104.","Company expects no impact to day-to-day business operations.","Trading of new common stock begins July 2, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":671918118.718232,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161376,"accession_number":"0000950170-25-079685","cik":1850270,"company_name":"PROKIDNEY CORP.","ticker":"PROK","form_type":"8-K","filed_at":"2025-05-30T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"ProKidney shareholders approve reincorporation from Cayman Islands to Delaware","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Domestication approved with 227.6M for, 1.1M against; expected completion by end of Q3 2025.","New Delaware charter adopted; authorized shares set at 700M Class A, 500M Class B, 50M preferred.","Directors Culleton, Legorreta, Sinha elected to three-year terms (avg ~226M for each).","Ernst & Young ratified as independent auditor for fiscal year 2025 (238.6M for).","Advisory charter proposals approved, including exclusive forum, written consent removal, supermajority vote requirements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.15,"market_cap_usd":671918118.718232,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161375,"accession_number":"0000950170-25-069254","cik":1850270,"company_name":"PROKIDNEY CORP.","ticker":"PROK","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ProKidney Q1 net loss $38M; cash $328.5M; REGEN-007 data due Q2 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss before noncontrolling interest was $38.0M for Q1 2025 vs $35.3M in Q1 2024.","Cash, cash equivalents and marketable securities totaled $328.5M as of March 31, 2025, funding operations into mid-2027.","Full data from Group 1 of Phase 2 REGEN-007 study expected in Q2 2025 (approx. 20 patients, ~18 months follow-up).","FDA confirmed accelerated approval pathway for rilparencel in Q4 2024; details expected mid-2025 after Type B meeting.","R&D expenses flat at $27.3M; G&A increased to $14.4M from $12.8M in prior-year period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":230000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":671918118.718232,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179538,"accession_number":"0000950170-25-040417","cik":1850270,"company_name":"PROKIDNEY CORP.","ticker":"PROK","form_type":"8-K","filed_at":"2025-03-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ProKidney posts FY2024 net loss of $163.3M; FDA confirms accelerated approval path for rilparencel","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss before noncontrolling interest $163.3M in 2024 vs $135.4M in 2023; R&D expenses rose 20% to $127.7M.","Cash and equivalents $358.3M at year-end; secured $140M equity to fund operations into mid-2027.","FDA confirmed accelerated approval pathway for rilparencel using eGFR slope as potential surrogate endpoint; PROACT 2 discontinued.","Full Phase 2 REGEN-007 Group 1 data expected Q2 2025; interim June 2024 showed 18-month kidney function stabilization.","Phase 3 PROACT 1 single study may support BLA; additional FDA meeting details expected mid-2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":671918118.718232,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179537,"accession_number":"0000950170-25-007217","cik":1850270,"company_name":"PROKIDNEY CORP.","ticker":"PROK","form_type":"8-K","filed_at":"2025-01-21T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"ProKidney sells Greensboro, NC property for ~$20.5M in cash; close expected March 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sale of real property in Greensboro, NC for approximately $20.5 million in cash.","Transaction expected to close in March 2025, subject to customary closing conditions.","Seller is ProKidney's wholly owned subsidiary, ProKidney Acquisition Company, LLC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":671918118.718232,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196263,"accession_number":"0000950170-24-130207","cik":1850270,"company_name":"PROKIDNEY CORP.","ticker":"PROK","form_type":"8-K","filed_at":"2024-11-22T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"ProKidney to acquire two Winston-Salem buildings for $22.5M for rilparencel manufacturing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Purchase price of $22.5 million in cash for two buildings totaling ~180,000 sq ft.","Buildings will support manufacturing operations for lead product candidate rilparencel.","Transaction expected to close by end of November 2024, subject to customary conditions.","Company currently occupies portions of the buildings under existing leases.","Agreement contains customary representations; no financing contingency disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":671918118.718232,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196262,"accession_number":"0000950170-24-124585","cik":1850270,"company_name":"PROKIDNEY CORP.","ticker":"PROK","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"FDA confirms PROACT 1 Phase 3 may support full approval; Q3 cash $406.8M","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA Type B meeting confirms PROACT 1 Phase 3 could be sufficient for BLA; accelerated approval pathway available using eGFR slope as surrogate endpoint.","Cash, equivalents and marketable securities $406.8M at Sept 30, 2024, expected to fund operations into 2027.","Q3 2024 net loss before noncontrolling interest $41.1M vs $42.0M in Q3 2023; R&D $31.3M, G&A $17.7M including $5.3M impairment.","Presented five posters at ASN Kidney Week including Phase 2 REGEN-007 late-breaking data.","Shares outstanding: 291,661,950 Class A and B ordinary shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":671918118.718232,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212548,"accession_number":"0000950170-24-102554","cik":1850270,"company_name":"PROKIDNEY CORP.","ticker":"PROK","form_type":"8-K","filed_at":"2024-09-03T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"ProKidney refocuses Phase 3 program; discontinues PROACT 2, expects topline results Q3 2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Discontinues ex-U.S. PROACT 2 trial; believes PROACT 1 alone may support FDA approval under RMAT designation.","Estimated topline results from PROACT 1 by Q3 2027; expects $150-175M expense reduction.","Cash runway extended to Q1 2027; focused on U.S. market for rilparencel in advanced CKD with type 2 diabetes.","CEO cites positive REGEN-007 interim data as supporting urgency; RMAT designation granted Oct 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":671918118.718232,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212547,"accession_number":"0000950170-24-094341","cik":1850270,"company_name":"PROKIDNEY CORP.","ticker":"PROK","form_type":"8-K","filed_at":"2024-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ProKidney reports Q2 net loss $38.5M, cash $431.5M, restarts Phase 3 trials","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Interim Phase 2 REGEN-007 data show kidney function stabilization for 18 months in diabetes/advanced CKD patients.","Manufacturing restarted; QP Declaration of Equivalence received in July; PROACT 1 and 2 trials resumed.","Closed $140M upsized equity offering in June, extending cash runway into mid-2026.","Cash & equivalents $431.5M at June 30, 2024 (vs $363.0M Dec 31, 2023).","R&D expenses $29.4M (Q2 2024) vs $26.4M (Q2 2023); net loss $38.5M vs $34.8M."],"consensus_eps_estimate":-0.1469,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":671918118.718232,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231548,"accession_number":"0001193125-24-160339","cik":1850270,"company_name":"PROKIDNEY CORP.","ticker":"PROK","form_type":"8-K","filed_at":"2024-06-13T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"ProKidney prices upsized $130M offering of 53.7M shares at $2.42 per share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Total offering of 53,719,009 shares at $2.42/share; net proceeds expected ~$136.7M.","Public offering of 42,744,220 shares; underwriters have 30-day option for 6,411,633 more.","Concurrent direct offering of 11,030,574 shares to certain investors; closings not contingent.","Expected close June 13; proceeds for clinical trials, R&D, pre-commercial activities.","Jefferies, J.P. Morgan, Guggenheim lead underwriting; PJT Partners as co-manager/adviser."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":671918118.718232,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231547,"accession_number":"0001193125-24-157913","cik":1850270,"company_name":"PROKIDNEY CORP.","ticker":"PROK","form_type":"8-K","filed_at":"2024-06-10T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"ProKidney reports REGEN-007 Phase 2 interim: eGFR stable over 18 months; manufacturing resumed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["In Group 1 (n=13), average eGFR change from baseline was -1.3 ml/min/1.73m² at 18 months; subset meeting Phase 3 criteria (n=10) showed -0.6.","No rilparencel-related serious adverse events in any of the 49 patients who received at least one injection.","Manufacturing resumed effective June 1, 2024 for U.S. and non-European clinical sites.","Anticipates QP Declaration of Equivalence to EU GMPs by end of June 2024 to enable European shipments.","PROACT 1 screening resumed under amended protocol enriched for higher risk patients; PROACT 2 activated sites in Spain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":671918118.718232,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231546,"accession_number":"0000950170-24-067341","cik":1850270,"company_name":"PROKIDNEY CORP.","ticker":"PROK","form_type":"8-K","filed_at":"2024-05-31T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"ProKidney shareholders elect directors, ratify auditor at 2024 AGM","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Jennifer Fox elected to board with 180,074,590 votes for, 1,649,737 against, 218 abstain.","José Ignacio Jiménez Santos elected with 180,893,693 for, 830,587 against, 265 abstain.","Ratification of Ernst & Young as auditor: 182,470,555 for, 4,195,327 against, 2,149 abstain.","Votes were cast at the May 30, 2024 Annual General Meeting of Shareholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":671918118.718232,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231545,"accession_number":"0001140361-24-027808","cik":1850270,"company_name":"PROKIDNEY CORP.","ticker":"PROK","form_type":"8-K","filed_at":"2024-05-29T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"ProKidney provides final Phase 2 RMCL-002 data; specifics not in filing text","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company furnished investor presentation with final data from Phase 2 RMCL-002 clinical trial.","Presentation available on ProKidney's website; full data not included in 8-K excerpt.","Trial targets dialysis prevention; efficacy/safety figures not disclosed in filing.","No financial or operational updates beyond the trial data release."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":671918118.718232,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231544,"accession_number":"0000950170-24-057443","cik":1850270,"company_name":"PROKIDNEY CORP.","ticker":"PROK","form_type":"8-K","filed_at":"2024-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ProKidney reports Q1 net loss $35.3M, cash $329M; Phase 2 data to be presented May 25","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["RMCL-002 Phase 2 final results to be presented at ERA Congress on May 25, 2024; investor call on May 28.","PROACT 1 protocol amendment submitted to FDA focusing on severe CKD (eGFR 20-35); enrollment to resume mid-2024.","Appointed Ulrich Ernst as EVP Technical Operations and Lucio Tozzi as SVP Global Clinical Operations.","Cash and equivalents $329M as of March 31, 2024, supporting operations into Q4 2025.","Net loss before noncontrolling interest $35.3M for Q1 2024 vs $36.9M same period 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":671918118.718232,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249898,"accession_number":"0000950170-24-035914","cik":1850270,"company_name":"PROKIDNEY CORP.","ticker":"PROK","form_type":"8-K","filed_at":"2024-03-25T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"ProKidney appoints EVP Technical Operations and SVP Global Clinical Operations","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ulrich Ernst appointed EVP Technical Operations; base salary $450,000, target bonus 40%.","Ernst receives option for 500,000 Class A shares; 335,000 time-vesting, 165,000 performance-vesting.","Lucio Tozzi appointed SVP Global Clinical Operations on Jan 22, 2024; over 30 years experience.","Both executives join Leadership Team to support Phase 3 program and BLA preparation.","Ernst previously SVP at Iovance Biotherapeutics; Tozzi held senior roles at Summit Therapeutics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":671918118.718232,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249897,"accession_number":"0000950170-24-034961","cik":1850270,"company_name":"PROKIDNEY CORP.","ticker":"PROK","form_type":"8-K","filed_at":"2024-03-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ProKidney FY2023 net loss $135.4M; cash $363M; positive Phase 2 data; mfg pause","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss before noncontrolling interest $135.4M vs $148.1M in 2022; cash $363.0M, funding into Q4 2025.","R&D expenses $106.7M, up $24.6M on Phase 3 costs; G&A $44.8M, down $26.1M on lower equity comp.","Appointed Dr. Bruce Culleton as CEO and Nikhil Pereira-Kamath as Chief Business Officer.","Positive interim Phase 2 RMCL-002 data showed kidney function preservation; PROACT 1 enrollment modified to eGFR 20-35.","Manufacturing paused for protocol amendment and QP audit; expects PROACT 1 and PROACT 2 enrollment to resume mid-2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":671918118.718232,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249893,"accession_number":"0000950170-24-032827","cik":1850270,"company_name":"PROKIDNEY CORP.","ticker":"PROK","form_type":"8-K/A","filed_at":"2024-03-18T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"ProKidney Corp. finalizes separation agreement with former COO Deepak Jain including $495K severance","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Severance pay of $495,000 (12 months base salary) plus eligibility for 2023 bonus up to 45% of base salary.","Company will pay 100% of COBRA/Medicare premiums through November 30, 2024.","Legal fee reimbursement up to $20,000 for negotiation of separation agreement.","Vested stock options exercisable for 90 days after effective date; all unvested awards forfeited.","Vested Class B shares: 783,969 convertible to Class A; 406,087 remain under lockup until July 11, 2026 or regulatory event."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":671918118.718232,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249892,"accession_number":"0000950170-24-032821","cik":1850270,"company_name":"PROKIDNEY CORP.","ticker":"PROK","form_type":"8-K/A","filed_at":"2024-03-18T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"ProKidney finalizes separation agreement with ex-CEO Bertram; $620K severance plus benefits","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Company pays $620K severance, bonus up to 60% of base salary for 2023 based on scorecard.","COBRA/Medicare premiums paid 100% through May 31, 2025; legal fees reimbursed up to $20K.","Vested stock options exercisable for 90 days after effective date; unvested equity forfeited.","Vested Class B ordinary shares remain subject to lockup until July 11, 2026 or regulatory milestone.","Standard release, non-disparagement, cooperation, and continuing obligations included."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":671918118.718232,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}